Treatment of systemic-onset juvenile arthritis with canakinumab

4Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis.

Cite

CITATION STYLE

APA

Peitz, J., & Horneff, G. (2015, February 18). Treatment of systemic-onset juvenile arthritis with canakinumab. Open Access Rheumatology: Research and Reviews. Dove Medical Press Ltd. https://doi.org/10.2147/OARRR.S54215

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free